AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

AC Immune S.A.NASDAQ: ACIU

Accounts Payables · Q4 FY2025 · quarter ended Dec 2025

Accounts payables outflow grows to CHF 327.34K

Q4 FY2025 accounts payables was CHF 327.34K, compared with CHF 0 a year earlier. Trailing-twelve-month accounts payables was CHF 327.34K.

Context

  • Accounts payables amounted to 15.8% of revenue in FY2025, up 15.8 pp from a year earlier.
  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near CHF 327.34K or moves back toward the trailing-twelve-month quarterly average of CHF 81.84K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
CHF 327.34K— QoQ
Last fiscal yearDec 2025
-CHF 565.39K— YoY
LTMDec 2025
CHF 327.34K— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

CHF · from the cash flow

Latest · FY2025
(565.39K) CHF
Year-over-year change
—

Accounts Payables vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Accounts payables amounts to 9.2% of revenue for ACIU, versus a peer median of 91.3%.
ACIU Competitors
Accounts Payables for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$17.22M USD+128.8%—8.0%
ANNXAnnexon, Inc.LTM Mar 2026$6.67M USD+3.7%——
SLNSilence Therapeutics plcLTM Mar 2026$5.6M USD——608.1%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$2.21M USD-172.7%+55.8%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$1.98M USD+327.2%-39.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.7M USD+135.6%—5477.4%
CLLSCellectis S.A.LTM Mar 2026$1.34M USD-181.1%—2.0%
MREOMereo BioPharma Group plcLTM Mar 2026$456.35K USD+226.0%—91.3%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$337K USD—+15.3%—
ACIUAC Immune S.A.LTM Dec 2025CHF 327.34K CHF——9.2%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$204.79K USD-411.0%-70.8%—
Peer median (excluding ACIU) —+66.3%-12.2%91.3%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.